NovoCure rises on Q3 EPS, sales beat

Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. “The third quarter of 2017 was another period marked by growth across all key commercial metrics in all key markets. Compared to the same quarter in 2016, we achieved 131% revenue growth – our ninth consecutive quarter of triple-digit year-over-year growth – and 71% active patient growth. We significantly improved net revenues as a percentage of gross billings year-over-year and generated positive cash flow from operations for the first time in the company’s history. Optune is the first treatment in more than 10 years to increase median overall survival in newly diagnosed GBM, and we are focused on bringing Optune to as many patients with glioblastoma who may benefit from it,” CEO Asaf Danziger said in a press release. The company updated on clinical trial milestones, expecting to launch phase 3 pivotal trials in loc...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news

Related Links:

Publication date: 15 January 2019Source: Journal of Molecular Structure, Volume 1176Author(s): S. Murugavel, C. Ravikumar, G. Jaabil, Ponnusamy AlagusundaramAbstractPrevious research studies confirm that molecules containing 1,2,3-triazole moiety are potential anticancer agents which elevates effectiveness and reduces drug resistance. Present study was aimed to evaluate the anticancer activity of the synthesized novel title compound 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine (BTCP). The structural and spectral characteristics of BTCP were studied and compared with DFT results. NBO, HOM...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Publication date: Available online 19 September 2018Source: Advances in Biological RegulationAuthor(s): Mariana L. Oliveira, Padma Akkapeddi, Daniel Ribeiro, Alice Melão, João T. BarataAbstractInterleukin 7 (IL-7) and its receptor (IL-7R, a heterodimer of IL-7Rα and γc) are essential for normal lymphoid development. In their absence, severe combined immunodeficiency occurs. By contrast, excessive IL-7/IL-7R-mediated signaling can drive lymphoid leukemia development, disease acceleration and resistance to chemotherapy. IL-7 and IL-7R activate three main pathways: STAT5, PI3K/Akt/mTOR and MEK/Erk, u...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Publication date: January 2019Source: Biomedical Signal Processing and Control, Volume 47Author(s): Jijun Tong, Yingjie Zhao, Peng Zhang, Lingyu Chen, Lurong JiangAbstractAn automatic brain tumor segmentation method based on texture feature and kernel sparse coding from FLAIR (fluid attenuated inversion recovery) contrast-enhanced MRIs (magnetic resonance imaging) is presented in this paper. First, the MRIs are pre-processed to reduce noise, enhance contrast and correct the intensity non-uniformity. Then sparse coding is performed on the first order and second order statistical eigenvector extracted from original MRIs whic...
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
Simon Thompson, 32, from Kent, was rushed to hospital when a 'dental abscess' failed to improve despite antibiotics. He was later diagnosed with advanced Non Hodgkin's lymphoma.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
From 2011 to 2016, expenditure on cancer drugs in the United States rapidly accelerated. The first prospective study of its kind tallies the numbers.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Authors: Hilpert F, Du Bois A Abstract INTRODUCTION: Patient-reported outcomes (PROs), including quality-of-life considerations, are increasingly becoming key factors in clinical decision making. Areas covered: This review provides an overview of the current status of PROs in guiding clinical trial design and clinical decision making in patients with ovarian cancer and previews the future potential of PROs in these settings. Expert commentary: In ovarian cancer, considerable discord exists between patients and physicians regarding perceived symptom burden. During maintenance therapy, it is important that the most a...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
CONCLUSION: Trabectedin + PLD may be an option for patients with platinum-sensitive relapsed ovarian cancer, including those who have received two or more previous lines of platinum. PMID: 30223697 [PubMed - in process]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Authors: Ray-Coquard I Abstract OBJECTIVE: In patients with recurrent ovarian cancer, there are certain situations where further surgery and/or next-line platinum-based chemotherapy is not feasible or is not the best option. Multidisciplinary teams have a key role in reviewing available options and selecting the most appropriate intervention. METHODS: A case study of relapsed ovarian cancer illustrates some of the factors that shape decision-making and shows the potential of a non-platinum-based regimen in the context of limited platinum sensitivity. RESULTS: Taking into account the patient's individual cir...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line. Expert Rev Anticancer Ther. 2018 Oct;18(sup1):13-17 Authors: Colombo N Abstract OBJECTIVES: Ovarian cancer patients with relapse 6-12 months after last platinum treatment, who have received bevacizumab consolidation and are not BRCA mutant, represent a considerable therapeutic challenge. METHODS: By means of illustrative case study, this review evaluates various treatment strategies for use at first relapse in an ovarian ca...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Lung Cancer | Medical Devices | Mesothelioma | Neurology | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Profits and Losses